Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Research reveals the assembly dynamics of nucleocapsid protein condensates can be regulated by small molecules with therapeutic potential

Researchers developed a screening platform and identified molecules with anti-CoV activity.

12 Dec 2022

Structural studies pave the way for cancer drugs that could target only mutated versions

To design drugs that stall the growth of aggressive cancers, it helps to know the structures of the proteins that are revving the cancers' engines.

9 Dec 2022

Researchers seek to reduce Chikungunya virus-caused joint pain with new drug

Oregon Health & Science University researchers and partners are developing what could become the first-ever treatment against the debilitating joint pain that can last months or years after becoming infected with the emerging Chikungunya virus.

9 Dec 2022

Liver cancer study could help improve the safety of certain gene therapies for hemophilia

Research led by Randal J. Kaufman, Ph.D., has found that misfolded proteins in liver cells contribute to the development of liver cancer, shedding new light on the mysterious origins of one of the world's deadliest diseases.

7 Dec 2022

Metrion Biosciences and The KCNC1 Foundation Collaborate on New Ion Channel Modulators

...

From Metrion Biosciences Limited 7 Dec 2022

Pre-Plated Assay Solutions That Can Help Accelerate Biotech

In this interview, we speak with University of Warwick spin-out Cryologyx about their innovative new technology that hopes to revolutionize cell-based assays for researchers across life sciences and drug discovery.

From Cryologyx Ltd 6 Dec 2022

Collaborative work unravels hidden molecular secrets of age-related diseases

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced today the release of the first batch of results from the collaborative work directed to perform multi-omics-based analyses in the context of age-related diseases using an AI-driven target and drug discovery pipeline.

2 Dec 2022

Scaling up the production of customized immune cells for drug development and testing

To prevent testing on animals and create even more precise ways of testing therapeutics, the pharmaceutical industry is increasingly turning to human immune cells.

1 Dec 2022

Integrated approach addresses some of the biggest challenges in natural products drug discovery

Many successful drugs have their origins in natural sources such as plants, fungi, and bacteria, but screening natural products to identify potential drugs remains a difficult undertaking.

1 Dec 2022

New, nanotech-based strategy could enable safe, long-term treatment for autoimmune diseases

Scientists at Scripps Research have reported success in initial tests of a new, nanotech-based strategy against autoimmune diseases.

1 Dec 2022

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity.

1 Dec 2022

Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the launch of its High Throughput Screening (HTS) capability, as well as the expansion of its state-of-the-art lab and office facilities. Scott Maidment has been appointed as Head of HTS to lead the new service.

From Metrion Biosciences Limited 1 Dec 2022

Fingerprint-embedding framework can help find novel drug candidates

Researchers have developed a new computer framework that holds promise in the work to discover new drugs. Their framework uses an artificial intelligence method called convolutional neural network to provide global information about potential novel drug candidates.

30 Nov 2022

Cannabidiol and the shifting perspective of epilepsy drug discovery

Researchers discuss the research hat contributed to cannabidiol as a potential antiseizure medication in the 21st century.

29 Nov 2022

New computer-based platform could make drug discovery process more efficient and less expensive

Researchers at The University of Texas at Dallas and Novartis Pharmaceuticals Corp. have devised a computer-based platform for drug discovery that could make the process more effective, more efficient and less costly.

28 Nov 2022

Using human iPSC-derived cells to revolutionize the field of neurodegenerative disease

In this interview, we speak to Axol Bioscience about their human iPSC-derived cells and how they have the potential to revolutionize the field of neurodegenerative disease.

From Axol Bioscience Ltd 28 Nov 2022

Optibrium appoints Ian Smith as Chief Technology Officer

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian Smith as Chief Technology Officer (CTO), the latest in a number of senior-level hires for the Company.

From Optibrium Ltd. 23 Nov 2022

Scientists develop RNA-targeting strategy to repair genetic cause of ALS and dementia

Scientists at UF Scripps Biomedical Research have developed a potential medicine for a leading cause of ALS and dementia that works by eliminating disease-causing segments of RNA. The

22 Nov 2022

Cancer Research Horizons, Newcastle University extend strategic drug discovery alliance with Astex Pharmaceuticals

Cancer Research UK’s newly launched innovation engine, Cancer Research Horizons, and Newcastle University, have announced a further significant extension of their strategic drug discovery alliance with Astex Pharmaceuticals (UK) (‘Astex’), a biotechnology company dedicated to the discovery and development of novel small molecule therapeutics.

22 Nov 2022

Creating New Targeted Antibacterial Products to Help Tackle Antimicrobial Resistance

We speak to Matthew Dunne, Director for Drug Discovery at Micreos Pharmaceuticals, about the importance of creating new targeted antibacterial products.

22 Nov 2022

Drug Discovery News and Research

Further Reading

Research reveals the assembly dynamics of nucleocapsid protein condensates can be regulated by small molecules with therapeutic potential

Structural studies pave the way for cancer drugs that could target only mutated versions

Researchers seek to reduce Chikungunya virus-caused joint pain with new drug

Liver cancer study could help improve the safety of certain gene therapies for hemophilia

Metrion Biosciences and The KCNC1 Foundation Collaborate on New Ion Channel Modulators

Pre-Plated Assay Solutions That Can Help Accelerate Biotech

Collaborative work unravels hidden molecular secrets of age-related diseases

Scaling up the production of customized immune cells for drug development and testing

Integrated approach addresses some of the biggest challenges in natural products drug discovery

New, nanotech-based strategy could enable safe, long-term treatment for autoimmune diseases

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities

Fingerprint-embedding framework can help find novel drug candidates

Cannabidiol and the shifting perspective of epilepsy drug discovery

New computer-based platform could make drug discovery process more efficient and less expensive

Using human iPSC-derived cells to revolutionize the field of neurodegenerative disease

Optibrium appoints Ian Smith as Chief Technology Officer

Scientists develop RNA-targeting strategy to repair genetic cause of ALS and dementia

Cancer Research Horizons, Newcastle University extend strategic drug discovery alliance with Astex Pharmaceuticals

Creating New Targeted Antibacterial Products to Help Tackle Antimicrobial Resistance

eBook: Essential guide to organoids in drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News